Published in Environ Res on February 01, 1998
Lead exposure and cardiovascular disease--a systematic review. Environ Health Perspect (2006) 3.11
Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol (2008) 1.41
Heavy metal poisoning and cardiovascular disease. J Toxicol (2011) 1.24
Protective effect of EDTA preadministration on renal ischemia. BMC Nephrol (2006) 0.87
Oxidative effects of lead in young and adult Fisher 344 rats. Arch Environ Contam Toxicol (2003) 0.85
The emerging role of outdoor and indoor air pollution in cardiovascular disease. N Am J Med Sci (2013) 0.81
The effect of chelation on blood pressure in lead-exposed children: a randomized study. Environ Health Perspect (2006) 0.79
Effect of ascorbic acid supplementation on nitric oxide metabolites and systolic blood pressure in rats exposed to lead. Indian J Pharmacol (2010) 0.76
Lead-Induced Cell Cycle Arrest in Human Liver Carcinoma (HepG2) Cells: Involvement of oxidative stress, p53 and Cyclin A. Met Ions Biol Med (2015) 0.75
Chronic lead exposure decreases the vascular reactivity of rat aortas: the role of hydrogen peroxide. PLoS One (2015) 0.75
Combination therapy for the cardiovascular effects of perinatal lead exposure in young and adult rats. Arq Bras Cardiol (2014) 0.75
Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation. Am Heart J (1999) 1.60
The adult Fanconi syndrome: observations on etiology, morphology, renal function and mineral metabolism in three patients. Medicine (Baltimore) (1972) 1.46
Kidney transplantation. A comparison of results using cadaver and related living donors. Am J Med (1969) 1.46
Effects of chronic spinal cord injury and pressure ulcer on 25(OH)-vitamin D levels. J Am Paraplegia Soc (1993) 1.46
Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. Pediatr Pathol (1989) 1.46
Activation of intrinsic coagulation pathway in pre-eclampsia. Am J Med (1986) 1.41
Effects of cyclosporine on magnesium metabolism in rats. J Lab Clin Med (1989) 1.39
Toxicity with intravenous injection of crude marijuana extract. Clin Toxicol (1981) 1.36
The quantitative estimation of perfusible glomeruli and the collagen and non-collagen nitrogen of the normal kidney. Nephron (1967) 1.28
Naïve and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int (2006) 1.27
Adult mouse kidneys become permissive to acute polyomavirus infection and reactivate persistent infections in response to cellular damage and regeneration. J Virol (1993) 1.27
Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest (2000) 1.26
Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and -resistant rat kidneys. Am J Nephrol (2007) 1.25
Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol (1985) 1.24
Silicon nephropathy. Am J Med (1975) 1.17
Experimental model of lead nephropathy. I. Continuous high-dose lead administration. Kidney Int (1992) 1.17
Osteopenia induced by long-term, low- and high-level exposure of the adult rat to lead. Miner Electrolyte Metab (1997) 1.16
Diphosphonate treatment of Paget's disease. Clin Orthop Relat Res (1976) 1.16
Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int (2006) 1.15
Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am J Hypertens (2000) 1.12
Renal magnesium wasting associated with amphotericin B therapy. Am J Med (1984) 1.12
Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species. Hypertension (1997) 1.10
Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab (2000) 1.10
Urolithiasis in patients with spinal cord injury. Paraplegia (1981) 1.07
Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrol (1994) 1.06
Simultaneous measurement of marinobufagenin, ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens (1998) 1.06
Circulating inhibitor of sodium-potassium-activated adenosine triphosphatase after expansion of extracellular fluid volume in rats. Clin Sci Mol Med (1977) 1.04
Effect of salt loading on nitric oxide synthase expression in normotensive rats. Am J Hypertens (2001) 1.04
Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int (2001) 1.03
Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension (1999) 1.03
Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int (1997) 1.03
Lead-induced hypertension: possible role of endothelial factors. Am J Hypertens (1993) 1.03
Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol (2010) 1.01
Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology (1997) 1.01
Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome. Am J Med Sci (1981) 1.01
Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther (2000) 1.00
Subclinical effects of chronic increased lead absorption--a prospective study. II. Results of baseline neurologic testing. J Occup Med (1979) 0.97
Hemorrhagic pneumonitis after intravenous injection of charcoal lighter fluid. Ann Intern Med (1979) 0.97
Hemodialysis in treatment of acute chloral hydrate poisoning. South Med J (1977) 0.96
Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy (1994) 0.96
Regulatory aspects of oxalate secretion in enteric oxalate elimination. J Am Soc Nephrol (1999) 0.95
Functional impairment in chronic renal disease. 3. Studies of potassium excretion. Am J Med Sci (1971) 0.95
Urinary -glucuronidase activity in renal disease. Arch Intern Med (1973) 0.94
Nephrotoxicity of paraquat in man. Arch Intern Med (1979) 0.94
Erythrocyte lead-binding protein after occupational exposure. I. Relationship to lead toxicity. Environ Res (1980) 0.94
Experimental Fanconi syndrome. I. Effect of maleic acid on renal cortical Na-K-ATPase activity and ATP levels. J Lab Clin Med (1970) 0.94
Compression neuropathy subsequent to renal transplantation. Urology (1976) 0.93
Renal senescence in 2008: progress and challenges. Int Urol Nephrol (2008) 0.92
Renal handling of calcium, magnesium and inorganic phosphate in chronic renal failure. Isr J Med Sci (1967) 0.92
Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs (1993) 0.92
Cardiovascular effects of lead exposure. Indian J Med Res (2008) 0.91
Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways. Am J Physiol (1999) 0.91
Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int (1999) 0.91
Bicarbonate-buffered peritoneal dialysis. An effective adjunct in the treatment of lactic acidosis. Am J Med (1979) 0.90
Phencyclidine intoxication: clinical experience in 27 cases confirmed by urine assay. Ann Emerg Med (1981) 0.90
Respiratory alkalosis. Respir Care (2001) 0.90
Functional abnormalities in experimental pyelonephritis. I. Studies of concentrating ability. Nephron (1965) 0.89
Central retinal vein occlusion associated with hemodialysis. Am J Med Sci (1979) 0.89
Thyroid function studies in the nephrotic syndrome. Ann Intern Med (1979) 0.89
Experimental model of lead nephropathy. III. Continuous low-level lead administration. Arch Environ Health (1993) 0.89
Vascular hyporesponsiveness in simulated microgravity: role of nitric oxide-dependent mechanisms. J Appl Physiol (1985) (2000) 0.89
Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Arch Intern Med (1984) 0.88
Cystic transformation of end-stage kidneys in patients undergoing hemodialysis. Int J Artif Organs (1980) 0.88
Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension (1998) 0.88
Effect of extracellular volume expansion on renal Na-K-ATPase and cell metabolism. Nephron (1974) 0.87
Femoral neuropathy: a complication of renal transplantation. Nephron (1981) 0.87
Effect of severe aortic banding above the renal arteries on nitric oxide synthase isotype expression. Kidney Int (2001) 0.87
Malignant or accelerated hypertension. West J Med (1984) 0.87
Enhanced NO inactivation and hypertension induced by a high-fat, refined-carbohydrate diet. Hypertension (2000) 0.86
Nephrotic syndrome associated with adenocarcinoma of the breast. Am J Med (1980) 0.86
Effect of chelation treatment with dimercaptosuccinic acid (DMSA) on lead-related blood pressure changes. Environ Res (1994) 0.86
Kidney transplantation in children. Pediatrics (1970) 0.86
Erythrocyte lead-binding protein after occupational exposure. II. Influence on lead inhibition of membrane Na+,K+-adenosinetriphosphatase. J Toxicol Environ Health (1981) 0.86
Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure. Am J Physiol Endocrinol Metab (2002) 0.86
A critical reappraisal of "acid-base" balance. Am J Clin Nutr (1969) 0.86
Erythropoiesis associated with viral hepatitis in end stage renal disease. Am J Med Sci (1984) 0.85
Characteristics of the transport of oxalate and other ions across rabbit proximal colon. Pflugers Arch (1993) 0.85
Maintenance hemodialysis in myeloma kidney disease. West J Med (1977) 0.85
Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci (Lond) (1994) 0.85
Prediction of creatinine clearance from serum creatinine in spinal cord injury patients. Paraplegia (1983) 0.84
Colorimetric rate method for the determination of creatinine as implemented by the Beckman Creatinine Analyzer 2. Am J Med Technol (1980) 0.84
Nitric oxide synthase isotype expression in salt-sensitive and salt-resistant Dahl rats. Hypertension (1999) 0.84
Conductive pathways for chloride and oxalate in rabbit ileal brush-border membrane vesicles. Am J Physiol (1998) 0.84
Functional impairment in chronic renal disease. I. Studies of sodium-conserving ability. Nephron (1966) 0.84
Effect of urea-saline diuresis on renal clearance of calcium, magnesium, and inorganic phosphate in man. Proc Soc Exp Biol Med (1966) 0.84
HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol (2004) 0.84
In vitro inhibition of Na-K-ATPase by trace metals: relation to renal and cardiovascular damage. Nephron (1986) 0.84
The prolonged use of methenamine hippurate in the treatment of chronic urinary tract infection. J Urol (1968) 0.83
Lung pathology in chronic hemodialysis patients. Int J Artif Organs (1982) 0.83
Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol (2008) 0.83
Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int (1997) 0.83
Renal function abnormalities in patients with asymptomatic hyperuricemia. Arthritis Rheum (1976) 0.83
Adrenocortical function during intermittent corticosteroid therapy. Ann Intern Med (1966) 0.83
Acquired renal cystic disease in renal transplant recipients. Nephron (1984) 0.83
Lead-induced hypertension is not associated with altered vascular reactivity in vitro. Am J Hypertens (1997) 0.83
Nephrotic syndrome and coagulation and fibrinolytic abnormalities. Am J Nephrol (1983) 0.83
Effect of continuous ambulatory peritoneal dialysis on blood pressure control. Am J Kidney Dis (1993) 0.83
The effect of modified transurethral sphincterotomy on autonomic dysreflexia. J Urol (1986) 0.82